Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Faes Farma ( (ES:FAE) ).
Faes Farma, S.A. has announced the acquisition of Laboratorios Edol, a leading Portuguese ophthalmology laboratory, for 75 million euros. This strategic move is expected to double Faes Farma’s sales and EBITDA in Portugal, enhance its international market presence, and create synergies with its current R&D team, particularly in the growing field of ophthalmology.
More about Faes Farma
Faes Farma, S.A. is a pharmaceutical company with a strong presence in the Portuguese market, specializing in the development and commercialization of pharmaceutical products. The company has a diverse portfolio that includes ophthalmology products, and it has been operating in the industry for over 80 years.
YTD Price Performance: 2.46%
Average Trading Volume: 15,993
Technical Sentiment Signal: Sell
Current Market Cap: €1.1B
For a thorough assessment of FAE stock, go to TipRanks’ Stock Analysis page.